{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:01:20Z","timestamp":1789704080638,"version":"4.0.1"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2015,7,29]],"date-time":"2015-07-29T00:00:00Z","timestamp":1438128000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2015,7,29]],"date-time":"2015-07-29T00:00:00Z","timestamp":1438128000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Dermatol"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1111\/bjd.13743","type":"journal-article","created":{"date-parts":[[2015,2,21]],"date-time":"2015-02-21T07:39:24Z","timestamp":1424504364000},"page":"842-845","source":"Crossref","is-referenced-by-count":36,"title":["The risk of nail changes with taxane chemotherapy: a systematic review of the literature and meta-analysis"],"prefix":"10.1093","volume":"173","author":[{"given":"K.","family":"Capriotti","sequence":"first","affiliation":[{"name":"Bryn Mawr Skin and Cancer Institute; Rosemont PA U.S.A"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"Capriotti","sequence":"additional","affiliation":[{"name":"Ophthalmology Consultants PC; Juan F. Luis Hospital; Christiansted VI U.S.A"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Lessin","sequence":"additional","affiliation":[{"name":"Bryn Mawr Skin and Cancer Institute; Rosemont PA U.S.A"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Wu","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology; Department of Medicine; State University of New York at Stony Brook; Stony Brook NY U.S.A"},{"name":"Division of Hematology and Oncology; Department of Medicine; Northport VA Medical Center; Northport NY U.S.A"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Goldfarb","sequence":"additional","affiliation":[{"name":"Breast Cancer Medicine Service; Memorial Sloan Kettering Cancer Center; New York NY U.S.A"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.R.","family":"Belum","sequence":"additional","affiliation":[{"name":"Dermatology Service; Memorial Sloan Kettering Cancer Center; New York NY U.S.A"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.E.","family":"Lacouture","sequence":"additional","affiliation":[{"name":"Dermatology Service; Memorial Sloan Kettering Cancer Center; New York NY U.S.A"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,7,29]]},"reference":[{"key":"10.1111\/bjd.13743-BIB0001|bjd13743-cit-0001","unstructured":"Paclitaxel Approved Indications and Dosages. FDA Label: Taxol (Paclitaxel) Princeton, NJ Bristol-Myers Squibb Company 1992 http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/020262s049lbl.pdf"},{"key":"10.1111\/bjd.13743-BIB0002|bjd13743-cit-0002","unstructured":"Docetaxel Approved Indications and Dosages. FDA Label: Taxotere (Docetaxel) Bridgewater, NJ Aventis Pharmaceuticals Inc. 2004 http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2004\/020449s028lbl.pdf"},{"key":"10.1111\/bjd.13743-BIB0003|bjd13743-cit-0003","unstructured":"Nab-Paclitaxel Approved Indications and Dosages. FDA Label: Abraxane (Paclitaxel Nanoparticle Albumin-Bound) Summit, NJ Celgene Corporation 2005 http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/021660s037lbl.pdf"},{"key":"10.1111\/bjd.13743-BIB0004|bjd13743-cit-0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1568011023354290","article-title":"Mechanism of action of antitumor drugs that interact with microtubules and tubulin","volume":"2","author":"Jordan","year":"2002","journal-title":"Curr Med Chem Anticancer Agents"},{"key":"10.1111\/bjd.13743-BIB0005|bjd13743-cit-0005","first-page":"334","article-title":"The irreplaceable image: nail changes in onco-hematologic patients","volume":"86","author":"Vassallo","year":"2001","journal-title":"Haematologica"},{"key":"10.1111\/bjd.13743-BIB0006|bjd13743-cit-0006","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/annonc\/mdg050","article-title":"Taxane-induced nail changes: incidence, clinical presentation and outcome","volume":"14","author":"Minisini","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1111\/bjd.13743-BIB0007|bjd13743-cit-0007","unstructured":"Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events v3.0 http:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcaev3.pdf"},{"key":"10.1111\/bjd.13743-BIB0008|bjd13743-cit-0008","volume-title":"WHO Adverse Reaction Terminology (WHOART)","author":"World Health Organization","year":"1998"},{"key":"10.1111\/bjd.13743-BIB0009|bjd13743-cit-0009","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.det.2007.08.003","article-title":"Malignancy and cancer treatment-related hair and nail changes","volume":"26","author":"Hinds","year":"2008","journal-title":"Dermatol Clin"},{"key":"10.1111\/bjd.13743-BIB0010|bjd13743-cit-0010","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s00520-007-0232-0","article-title":"Nail changes due to docetaxel-a neglected side effect and nuisance for the patient","volume":"15","author":"Winther","year":"2007","journal-title":"Support Care Cancer"},{"key":"10.1111\/bjd.13743-BIB0011|bjd13743-cit-0011","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.det.2006.03.004","article-title":"Drug-induced nail diseases","volume":"24","author":"Piraccini","year":"2006","journal-title":"Dermatol Clin"},{"key":"10.1111\/bjd.13743-BIB0012|bjd13743-cit-0012","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/1078155208100450","article-title":"Nail toxicity induced by cancer chemotherapy","volume":"15","author":"Gilbar","year":"2009","journal-title":"J Oncol Pharm Pract"},{"key":"10.1111\/bjd.13743-BIB0013|bjd13743-cit-0013","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1046\/j.1365-2133.2001.04391.x","article-title":"Onychomadesis and onycholysis associated with capecitabine","volume":"145","author":"Chen","year":"2001","journal-title":"Br J Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjd.13743","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjd.13743","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/bjd.13743\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T14:14:19Z","timestamp":1676384059000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/173\/3\/842\/6627475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,29]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,9]]}},"URL":"https:\/\/doi.org\/10.1111\/bjd.13743","archive":["Portico"],"relation":{},"ISSN":["0007-0963"],"issn-type":[{"value":"0007-0963","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7,29]]}}}